Low molecular weight heparin and bleeding in patients with chronic renal failure

Current Opinion in Pulmonary Medicine

Volumn 13, Issue 5, 2007, Pages 409-413

  Crowther, Mark ^a   Lim, Wendy ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Bioaccumulation; Bleeding; Low molecular weight heparin; Renal failure

Indexed keywords

CREATININE; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN;

ACUTE CORONARY SYNDROME; ARTERY THROMBOSIS; BIOACCUMULATION; BLEEDING; CHRONIC KIDNEY FAILURE; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG PROTEIN BINDING; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; MOLECULAR WEIGHT; RECOMMENDED DRUG DOSE; REVIEW; VEIN THROMBOSIS;

ANTICOAGULANTS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

EID: 34748833550     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328216430d     Document Type: Review

References (15)

1. Van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004: CD001100.
2. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337:663-669.
3. Quinlan DJ, McQuillan A, Eikenboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism. Ann Intern Med 2004; 140:175-183.
4. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144:673-684. This systematic review is the first to carefully examine the risk of bleeding in patients with impaired renal function who are treated with LMWH.
5. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334:682-687.
6. Schraibman IG, Milne AA, Royle EM. Home versus in-patient treatment for deep vein thrombosis. Nurs Times 2001; 97:35.
7. Kearon C, Ginsberg JS, Julian JA, et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. J Am Med Assoc 2006; 296:935-942. This randomized controlled trial challenges the dogma that all patients with acute venous thromboembolism should be treated with either monitored unfractionated heparin or weight-adjusted LMWH.
8. Aventis Pharma Inc. Lovenox product monograph (enoxaparin sodium) [pamphlet]; 2006; http://www.fda.gov/cder/foi/label/2007/020164s070lbl.pdf. [Accessed 10 May 2007]
9. Siguret V, Pautas E, Fevrier M, et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000; 84:800-804.
10. Pautas E, Gouin I, Bellot O, et al. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Safety 2002; 25:725-733.
11. Rabbat CG, Cook DJ, Crowther MA, et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care 2005; 20:357-363.
12. Tincani E, Mannucci C, Casolari B, et al. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica 2006; 91:976-979.
13. Mahe I, Aghassarian M, Drouet L, et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function. A comparative pharmacokinetic study. Thromb Haemost 2007; 97:581-586.
14. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. J Am Med Assoc 2006; 295:1519-1530.
15. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin inacute coronary syndromes. N Engl J Med 2006;354:1464-1476. This critically important paper establishes the safety and efficacy of fondaparinux compared with enoxaparin in patients with acute coronary syndromes.